ACGT Awards $1.3 Million in New Grants

Nov 02, 2017

ACGT has awarded $1.3 million in new grants to three scientists studying immunotherapy and virotherapy in the treatment of glioblastoma, sarcoma and ovarian cancer.

“We have big hopes for these grants,” said John Walter, CEO and president of ACGT. “ACGT was one of the first funders to support Dr. Carl June’s work at the University of Pennsylvania in successfully treating leukemia with gene therapy when it was still deemed ‘risky’ science. The recent FDA approval of the first gene therapy treatment to come out of this research, Kymriah, validates the promise of this science. With these three new clinical investigator grants, we hope to see similar results with immunotherapy and virotherapy in treating hard-to-combat solid tumor cancers.”

The new grants are:

Nori Kasahara, MD, PhD – Virotherapy for Glioblastoma Brain Cancer
Co-Leader Viral Oncology Program
Sylvester Comprehensive Cancer Center, University of Miami

Dr. Kasahara’s research focuses on translational application of gene transfer technologies to cancer, transplantation and regenerative medicine. Dr. Kasahara will use his ACGT grant to advance a clinical trial for a virotherapy for glioblastoma. Using a modified retrovirus to deliver chemotherapy directly into cancer cells, these “suicide genes” continue to replicate to prevent recurrence. The work will take the experience in the lab and translate it to a patient clinical trial.

Seth Pollack, M.D. – Immunotherapy for Sarcoma
Fred Hutchinson Cancer Research Center, Seattle, Washington

Dr. Pollack’s research is focused on developing novel immunotherapies for patients with advanced sarcoma, specifically synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL). Dr. Pollack’s ACGT grant will further his research by using immunotherapy to target this rare form of cancer that grows in connective tissue – cells that support other body tissues such as in bones, muscles, tendons, etc. The initial clinical trial will deploy two different types of genetically engineered T cells to target the cancer and to assess efficacy and safety.

Daniel Powell, Jr., PhD — Immunotherapy for Ovarian Cancer
Director of Immunotherapy for Division of Gynecology
University of Pennsylvania Perelman School of Medicine

Dr. Powell’s research focuses on the development of innovative immunotherapeutic strategies, including adoptive immunotherapy, using chimeric antigen receptor (CAR) T cells. Dr. Powell will used his ACGT grant to enroll nine ovarian cancer patients in a new clinical trial. Immune system killer T cells will be developed outside the body and reinserted to establish an offense against the disease and a defense against recurrence.